Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, André Goy et al.|Annals of Oncology|2014Cited by 138
Detection of stool DNA mutations before and after treatment of colorectal neoplasiaSapna Syngal, Michael W. Ross, Elena M. Stoffel et al.|Cancer|2005Cited by 49
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37
Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipientsBetty K. Hamilton, Navneet S. Majhail, Arjun Law et al.|Bone Marrow Transplantation|2015Cited by 32
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2021Cited by 15